335 related articles for article (PubMed ID: 31923859)
1. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
2. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
4. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
6. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
7. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
8. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
[TBL] [Abstract][Full Text] [Related]
10. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
[TBL] [Abstract][Full Text] [Related]
12. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
Wang ZH; Li DD; Chen WL; You QD; Guo XK
Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
[TBL] [Abstract][Full Text] [Related]
14. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
17. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
19. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
20. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]